Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

BioXcel Therapeutics (BTAI) Cost of Revenue (2022 - 2025)

BioXcel Therapeutics has reported Cost of Revenue over the past 4 years, most recently at $32000.0 for Q4 2025.

  • Quarterly results put Cost of Revenue at $32000.0 for Q4 2025, down 96.15% from a year ago — trailing twelve months through Dec 2025 was $164000.0 (down 92.35% YoY), and the annual figure for FY2025 was $164000.0, down 92.35%.
  • Cost of Revenue for Q4 2025 was $32000.0 at BioXcel Therapeutics, up from $11000.0 in the prior quarter.
  • Over the last five years, Cost of Revenue for BTAI hit a ceiling of $1.2 million in Q3 2024 and a floor of $9000.0 in Q4 2022.
  • Median Cost of Revenue over the past 4 years was $47000.0 (2024), compared with a mean of $256357.1.
  • Biggest five-year swings in Cost of Revenue: soared 7833.33% in 2023 and later crashed 99.06% in 2025.
  • BioXcel Therapeutics' Cost of Revenue stood at $9000.0 in 2022, then soared by 7833.33% to $714000.0 in 2023, then increased by 16.53% to $832000.0 in 2024, then plummeted by 96.15% to $32000.0 in 2025.
  • The last three reported values for Cost of Revenue were $32000.0 (Q4 2025), $11000.0 (Q3 2025), and $107000.0 (Q2 2025) per Business Quant data.